One of the drugs used in CRC is regorafenib (REG), which is recommended for patients with metastatic colorectal cancer (CRC), including those who have failed treatment with fluoropyrimidine-based chemotherapy or treatment with an anti-VEGF or anti-EGFR agent. The gene discussed is EGFR; the disease is colorectal carcinoma.